Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds (Q36045944)

11 August 2017

1 reference

title

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds (English)

1 reference

11 August 2017

Matthew M Cooney

1

1 reference

11 August 2017

Jose Ortiz

series ordinal

2

1 reference

11 August 2017

Ronald M Bukowski

series ordinal

3

1 reference

11 August 2017

Scot C Remick

series ordinal

4

1 reference

11 August 2017

1 March 2005

1 reference

11 August 2017

Current Oncology Reports

1 reference

11 August 2017

7

1 reference

11 August 2017

2

1 reference

11 August 2017

90-95

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-005-0033-x

11 August 2017

0 references

cites work

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-005-0033-X

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

21 January 2018

1 reference

12 December 2020

Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins

1 reference

12 December 2020

Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

1 reference

12 December 2020

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy

1 reference

12 December 2020

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

1 reference

12 December 2020

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

12 December 2020

Tumor progression: potential role of unstable genomic changes

1 reference

12 December 2020

Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells

1 reference

12 December 2020

Hypoxic Stress Proteins: Survival of the Fittest

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

12 December 2020

A novel K+ channel blocker isolated from 'hiccup nut' toxin

1 reference

12 December 2020

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

12 December 2020

Microvascular corrosion casting in the study of tumor vascularity: a review.

1 reference

12 December 2020

Vascular targeting agents as cancer therapeutics

1 reference

12 December 2020

Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer

1 reference

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

12 December 2020

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

12 December 2020

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

12 December 2020

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

1 reference

12 December 2020

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

12 December 2020

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

12 December 2020

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

12 December 2020

Isolation and structure of combretastatin

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1139/V82-202

Identifiers

DOI

10.1007/S11912-005-0033-X

1 reference

11 August 2017

1 reference